Atezolizumab not cost effective in advanced NSCLC

    This is a preview of subscription content, log in to check access.


    1. 1.

      2018 US dollars

    2. 2.

      epidermal growth factor receptor

    3. 3.

      anaplastic lymphoma kinase


    1. Lin S, et al. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer. International Journal of Clinical Pharmacy : 11 Jun 2020. Available from: URL:

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Atezolizumab not cost effective in advanced NSCLC. PharmacoEcon Outcomes News 856, 5 (2020).

    Download citation